Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Drug Carrier Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Crossover Trial of Clopidogrel and Ticagrelor

NCT03161678
View directory record Official record
Conditions
Myocardial Infarction, Thrombosis, Platelet Dysfunction
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Not listed Not applicable Interventional

Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

NCT06074315
View directory record Official record
Conditions
Distal Lateral Subungual Onychomycosis, Onychomycosis
Interventions
Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only)
Device
Lead sponsor
Nail Genesis LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Fayetteville, Arkansas • Montclair, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 1, 2026, 9:54 AM EDT
Terminated Phase 2 Interventional

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747
View directory record Official record
Conditions
Shock, Sepsis, Hypotension, Critical Illness
Interventions
Tranexamic Acid, Control Intervention (Carrier fluid only)
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 1, 2026, 9:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT06340360
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 1 Interventional

Chlorhexidine Gel Therapy for Cariogenic Oral Microflora

NCT01036412
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
1% Chlorhexidine Gluconate Gel, Surveys
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cosmetic Effects of Topical Acetyl Zingerone

NCT03530787
View directory record Official record
Conditions
Wrinkle Appearance, Skin Pigment, Erythema, Side Effect, Microbiome, Lipidome
Interventions
Acetyl Zingerone Topical Cream, Topical cream
Other
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 1, 2026, 9:54 AM EDT
Terminated Phase 3 Interventional Results available

0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka

NCT03303794
View directory record Official record
Conditions
Anesthesia
Interventions
Exparel, 0.25% bupivacaine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 1, 2026, 9:54 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

NCT02616484
View directory record Official record
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Dichloroacetate (DCA), Placebo, Genotype
Drug · Other · Genetic
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
6 Months to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 1, 2026, 9:54 AM EDT
Terminated Phase 2 Interventional

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

NCT04621149
View directory record Official record
Conditions
COVID-19
Interventions
chlorine dioxide, zinc acetate, Famotidine, placebo, lactoferrin, green tea extract
Other · Dietary Supplement · Drug
Lead sponsor
Profact, Inc.
Other
Eligibility
20 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

NCT00361842
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Not applicable Interventional Results available

Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT01731470
View directory record Official record
Conditions
Interstitial Cystitis, Pelvic Pain
Interventions
Liposomes
Biological
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 1, 2026, 9:54 AM EDT
Completed No phase listed Observational

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 3 Interventional

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002319
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal)
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Berkeley, California • Beverly Hills, California • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Early Phase 1 Interventional Results available

ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

NCT03014726
View directory record Official record
Conditions
Stricture Urethra
Interventions
Urotronic Drug Coated Balloon (DCB)
Combination Product
Lead sponsor
Urotronic Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Brooklyn Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02642965
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Pharmacological Study
Drug · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 1, 2026, 9:54 AM EDT
Active, not recruiting Phase 4 Interventional

MR Antagonist and LSD1

NCT04840342
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Excess
Interventions
Eplerenone, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
17 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 1, 2026, 9:54 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS

NCT02087826
View directory record Official record
Conditions
Genetics, Metabolism, Type 2 Diabetes
Interventions
Mixed Meal Tolerance Test, Metformin
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Terminated Not applicable Interventional

A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity

NCT00176553
View directory record Official record
Conditions
Neurotoxicity Syndromes
Interventions
Dextromethorphan
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
2 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 3 Interventional

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

NCT04195945
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 1, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

NCT00580112
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Dexamethasone, Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Sep 1, 2026, 9:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 1, 2026, 9:54 AM EDT